Oncolytics Biotech

ONCY

Market cap $104M

SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Special Meeting of Shareholders (the “Special Meeting”) held on Thursday, January 15, 2026. Each item of business described in the management information circular/prospectus of the Company dated December 9, 2025, was approved by the shareholders.

Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript

Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR  Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous cell anal carcinoma (“SCAC”), a setting with no U.S. Food and Drug Administration (“FDA”)-approved treatment options. Previous analysis from this cohort has focused on second-line or later SCAC patients.

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided additional context regarding its previously announced proposal to change the Company's jurisdiction of incorporation from Alberta, Canada, to the State of Nevada in the United States.

SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the status of its intellectual property (“IP”) portfolio and ongoing efforts to extend patent protection for pelareorep as part of the company's long-term value creation and development strategy. In early Q3 2025, Oncolytics filed a Track 1 prioritized examination patent application with the United States P.

SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its gastrointestinal (“GI”) Tumor Scientific Advisory Board (“SAB”) with the appointment of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris, three globally recognized experts in gastrointestinal oncology. The GI SAB was recently established to support Oncolytics' growing portfolio of clinical p.

SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced clinical and translational findings supporting the development of pelareorep in second-line metastatic colorectal cancer (“mCRC”), specifically in patients with KRAS-mutant, microsatellite-stable (“MSS”) disease. This represents one of the most difficult-to-treat and least responsive subgroups within colorectal cancer.

SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed an amended registration statement on Form F-4 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) that includes a management circular/prospectus and other relevant documents related to various proposals contained therein, and that the Registration Statement has been decla.

The heavy selling pressure might have exhausted for Oncolytics Biotech (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has cancelled and will reschedule its special meeting of shareholders (the “Special Meeting”), as described in its news release dated October 20, 2025, which was to be held on December 15, 2025. The Special Meeting is being rescheduled due to delays at the Securities and Exchange Commission caused by the recent.